Michael Bigham - Paratek Pharmaceuticals Chairman of the Board, CEO
| PRTKDelisted Stock | USD 2.23 0.00 0.00% |
Chairman
Mr. Michael F. Bigham, CPA, is Executive Chairman of the Board of the Company. Mr. Bigham In June 2014, Paratek Pharmaceuticals, Inc. entered into an offer letter agreement, or the Bigham Agreement, with Mr. Bigham, pursuant to which he commenced employment on an atwill basis as our Chief Executive Officer. Pursuant to the terms of the Bigham Agreement, Mr. Bigham was to receive an initial annual base salary of 250, 000 under the terms of his agreement, Mr. Bigham has more than 25 years of senior leadership experience in the biopharmaceutical industry. From January 2003 to November 2015, he was a general partner at Abingworth LLP, a leading international investment group dedicated to life sciences and healthcare. In November 2015, Mr. Bigham became part time Executive Partner at the firm. He currently serves as a member of the board of directors of Adamas Pharmaceuticals and InMediata. He has held several directorships, including at Avila Therapeutics, Magellan Biosciences, Portola Pharmaceuticals, Supernus Pharmaceuticals, Avedro and Valeritas. Mr. Bigham was formerly Vice Chairman of Corixa Corporationrationration, a publicly traded biotechnology company, and was President and Chief Executive of Coulter Pharmaceuticals, a publiclytraded oncology company, until it merged into Corixa. Previously, he was an early employee at Gilead Sciences where he served in various capacities, including Executive Vice President of Operations and Chief Financial Officer. Before joining Gilead Sciences, Mr. Bigham was a Partner at Hambrecht Quist where he became CoHead of Healthcare Investment Banking since 2019.
| Age | 61 |
| Tenure | 5 years |
| Professional Marks | CPA |
| Phone | 617 807 6600 |
| Web | https://paratekpharma.com |
Paratek Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1799) % which means that it has lost $0.1799 on every $100 spent on assets. This is way below average. Paratek Pharmaceuticals' management efficiency ratios could be used to measure how well Paratek Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 258.41 M in liabilities with Debt to Equity (D/E) ratio of 3.2, implying the company greatly relies on financing operations through barrowing. Paratek Pharmaceuticals has a current ratio of 3.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Paratek Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Paratek Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Paratek Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Paratek to invest in growth at high rates of return. When we think about Paratek Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 8 records | CHAIRMAN Age | ||
| Jonathan Knowles | Adaptimmune Therapeutics Plc | 68 | |
| Thomas Hecht | Affimed NV | N/A | |
| Daniel Bradbury | Equillium | 63 | |
| Vernon Lobo | Equillium | 48 | |
| Roger Korman | Aptose Biosciences | N/A | |
| William Rice | Aptose Biosciences | 65 | |
| Richard Miller | Corvus Pharmaceuticals | 66 | |
| Harlan MD | Lyra TherapeuticsInc | 71 | |
Management Performance
| Return On Asset | -0.18 |
Paratek Pharmaceuticals Leadership Team
Elected by the shareholders, the Paratek Pharmaceuticals' board of directors comprises two types of representatives: Paratek Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Paratek. The board's role is to monitor Paratek Pharmaceuticals' management team and ensure that shareholders' interests are well served. Paratek Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Paratek Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vadim Muzyaev, President Deputy Chairman of the Board | ||
| Richard Lim, Independent Director | ||
| Robert Radie, Independent Director | ||
| Kristine Peterson, Independent Director | ||
| Vadim Yakunin, Chairman of the Board | ||
| Timofey Prokopov, Vice President for Finance and Investment | ||
| FACC FAHA, CEO Director | ||
| Vadim Gorbunov, Director | ||
| Rajesh Padmanabhan, Vice President - Information Technology | ||
| Stephen Villano, Vice President - Clinical and Medical Affairs | ||
| Jeanne Jew, Senior Vice President - Business Development | ||
| Sergey Anoshin, Director for Legal Issues | ||
| Ben Strain, VP CEO | ||
| William Haskel, Senior Vice President General Counsel, Corporate Secretary | ||
| Thomas Dietz, Independent Director | ||
| CPA CPA, Ex Chairman | ||
| Timothy Franson, Independent Director | ||
| Rolf Hoffman, Director | ||
| Leonid Sevastyanov, Independent Director | ||
| Karen McGrath, VP HR | ||
| Jeffrey Stein, Independent Director | ||
| Sarah Higgins, Interim Principal Financial Officer and Principal Accounting Officer | ||
| Michael Bigham, Chairman of the Board, CEO | ||
| Sergey Guz, Director | ||
| Evan Tzanis, Senior Vice President - Clinical Development and Clinical Operations | ||
| Randall Brenner, Chief Officer | ||
| Douglas Pagan, CFO | ||
| Aleksandr Sukhoruchenko, Independent Director | ||
| Anna Kinash, Chief Accountant | ||
| Evan Loh, President COO, Chief Medical Officer, Director | ||
| Regina Paglia, Senior Vice President - Human Resources | ||
| Adam Woodrow, Vice President and Chief Commercial Officer | ||
| Yuliya Yakunina, Director of Economics, Director | ||
| Jason Burdette, VP Operations |
Paratek Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Paratek Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.18 | |||
| Profit Margin | (0.35) % | |||
| Operating Margin | (0.25) % | |||
| Current Valuation | 345.3 M | |||
| Shares Outstanding | 57.32 M | |||
| Shares Owned By Insiders | 11.70 % | |||
| Shares Owned By Institutions | 55.08 % | |||
| Number Of Shares Shorted | 2.64 M | |||
| Price To Earning | (5.49) X | |||
| Price To Sales | 0.86 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Paratek Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Paratek Pharmaceuticals' short interest history, or implied volatility extrapolated from Paratek Pharmaceuticals options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Paratek Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Paratek Stock
If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |